JPMorgan Chase & Co. Raises Stock Holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

JPMorgan Chase & Co. boosted its holdings in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 9.1% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 408,261 shares of the biopharmaceutical company’s stock after acquiring an additional 33,888 shares during the quarter. JPMorgan Chase & Co. owned 0.34% of Catalyst Pharmaceuticals worth $8,116,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of CPRX. GAMMA Investing LLC grew its holdings in shares of Catalyst Pharmaceuticals by 62.1% in the third quarter. GAMMA Investing LLC now owns 1,778 shares of the biopharmaceutical company’s stock worth $35,000 after purchasing an additional 681 shares during the last quarter. nVerses Capital LLC purchased a new stake in Catalyst Pharmaceuticals in the 3rd quarter valued at about $50,000. Larson Financial Group LLC grew its stake in Catalyst Pharmaceuticals by 27,218.2% in the 3rd quarter. Larson Financial Group LLC now owns 3,005 shares of the biopharmaceutical company’s stock worth $60,000 after acquiring an additional 2,994 shares in the last quarter. Quantbot Technologies LP purchased a new stake in shares of Catalyst Pharmaceuticals in the third quarter valued at approximately $151,000. Finally, Point72 Asia Singapore Pte. Ltd. bought a new position in Catalyst Pharmaceuticals in the second quarter worth approximately $153,000. Hedge funds and other institutional investors own 79.22% of the company’s stock.

Insider Buying and Selling at Catalyst Pharmaceuticals

In other Catalyst Pharmaceuticals news, insider Gary Ingenito sold 12,000 shares of the business’s stock in a transaction dated Wednesday, November 27th. The stock was sold at an average price of $22.72, for a total transaction of $272,640.00. Following the sale, the insider now owns 51,391 shares in the company, valued at approximately $1,167,603.52. The trade was a 18.93 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Steve Miller sold 50,000 shares of the firm’s stock in a transaction dated Tuesday, December 10th. The stock was sold at an average price of $21.93, for a total value of $1,096,500.00. Following the completion of the transaction, the insider now owns 686,996 shares of the company’s stock, valued at approximately $15,065,822.28. The trade was a 6.78 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 79,500 shares of company stock worth $1,754,140. 11.00% of the stock is owned by insiders.

Catalyst Pharmaceuticals Trading Down 0.1 %

Shares of CPRX stock opened at $22.19 on Wednesday. Catalyst Pharmaceuticals, Inc. has a 12-month low of $13.12 and a 12-month high of $24.27. The business’s fifty day simple moving average is $21.78 and its 200-day simple moving average is $20.11. The company has a market cap of $2.65 billion, a PE ratio of 18.81, a PEG ratio of 3.35 and a beta of 0.79.

Analyst Ratings Changes

A number of brokerages have weighed in on CPRX. HC Wainwright lifted their target price on Catalyst Pharmaceuticals from $30.00 to $35.00 and gave the company a “buy” rating in a research report on Friday, January 10th. Bank of America restated a “buy” rating and issued a $30.00 price objective on shares of Catalyst Pharmaceuticals in a report on Thursday, January 9th. Stephens started coverage on shares of Catalyst Pharmaceuticals in a report on Monday, November 18th. They issued an “overweight” rating and a $35.00 price target for the company. Truist Financial increased their price objective on shares of Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the company a “buy” rating in a research note on Monday, November 11th. Finally, StockNews.com downgraded shares of Catalyst Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat, Catalyst Pharmaceuticals currently has an average rating of “Buy” and an average target price of $32.86.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.